IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury

Journal of the American Society of Nephrology

Volumn 27, Issue 1, 2016, Pages 293-304

  Lefaucheur, Carmen ^a,b   Viglietti, Denis ^a,b   Bentlejewski, Carol ^c   Van Huyen, Jean Paul Duong ^a,d   Vernerey, Dewi ^e   Aubert, Olivier ^b   Verine, Jérôme ^a   Jouven, Xavier ^b   Legendre, Christophe ^d   Glotz, Denis ^a   Loupy, Alexandre ^b,d   Zeevi, Adriana ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b National Institute of Health and Medical Research   (France)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4D; HLA ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; HLA ANTIGEN;

ACUTE ANTIBODY MEDIATED REJECTION; ADULT; ANTIBODY MEDIATED KIDNEY ALLOGRAFT INJURY; ARTICLE; ATROPHY; COMPLEMENT FIXATION; DONOR; FIBROSING ALVEOLITIS; FOLLOW UP; GLOMERULOPATHY; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MICROCIRCULATION; PATHOGENICITY; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; TIME; TUBULAR ATROPHY; ALLOGRAFT; ANTIBODY SPECIFICITY; CLASSIFICATION; FEMALE; HISTOCOMPATIBILITY; IMMUNOLOGY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATION;

ALLOGRAFTS; ANTIBODY SPECIFICITY; FEMALE; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TISSUE DONORS; TRANSPLANTATION IMMUNOLOGY;

EID: 84954411181     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014111120     Document Type: Article

References (50)

1. Sellarés J, de Freitas DG,MengelM, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF: Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 12: 388-399, 2012
2. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B: Lack of improvement in renal allograft survival despite amarked decrease in acute rejection rates over the most recent era. Am J Transplant 4: 378-383, 2004
3. Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, Schnitzler MA, Stewart DE, Cherikh WS, Wainright JL, Snyder JJ, Israni AK, Kasiske BL: OPTN/SRTR 2012 annual data report: Kidney. Am J Transplant 14 [Suppl 1]: 11-44, 2014
4. Rapport médical et scientifique de l'Agence de la biomédecine 2013 (www.agence-biomedecine.fr/annexes/bilan2013/donnees/sommaireorganes. htm)
5. Nankivell BJ, Alexander SI: Rejection of the kidney allograft. N Engl J Med 363: 1451-1462, 2010
6. Papadimitriou JC, Drachenberg CB, Ramos E, Kukuruga D, Klassen DK, Ugarte R, Nogueira J, Cangro C,WeirMR, Haririan A: Antibody-mediated allograft rejection: Morphologic spectrum and serologic correlations in surveillance and for cause biopsies. Transplantation 95: 128-136, 2013
7. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, Gautreau C, Charron D, Glotz D, Suberbielle-Boissel C: Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 21: 1398-1406, 2010
8. Chen G, Sequeira F, Tyan DB: Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 72: 849-858, 2011
9. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB: C1qfixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 91: 342-347, 2011
10. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Frémeaux-Bacchi V,Méjean A,Desgrandchamps F, AnglicheauD,Nochy D,CharronD, EmpanaJP, DelahousseM, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X: Complement-binding anti-HLA antibodies and kidney-allograft survival.NEngl J Med 369: 1215-1226, 2013
11. Tao MH, Smith RI, Morrison SL: Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J ExpMed 178: 661-667, 1993
12. Schaub S,HöngerG, KollerMT, Liwski R, Amico P:Determinants ofC1q binding in the single antigen bead assay. Transplantation 98: 387-393, 2014
13. Woof JM, Burton DR: Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 4: 89-99, 2004
14. van ZelmMC: B cells take their time: Sequential IgGclass switching over the course of an immune response? Immunol Cell Biol 92: 645-646, 2014
15. Sitaru C, Mihai S, Zillikens D: The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases. Arch Dermatol Res 299: 1-8, 2007
16. Azevedo CD, Bruña-Romero O, Marques SG, Nascimento FR, Pinto MC, Silva LA, Bouillet LE, Azevedo FS, StoianoffMA: Association of IgG immunoglobulin and subclasses level with the severity of chromoblastomycosis due to Fonsecaea pedrosoi and therapeutic response to itraconazole. Eur J Clin Microbiol Infect Dis 33: 1791-1797, 2014
17. Bijl M, Dijstelbloem HM, Oost WW, Bootsma H, Derksen RH, Aten J, Limburg PC, Kallenberg CG: IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus. Rheumatology (Oxford) 41: 62-67, 2002
18. Noël LH, Aucouturier P, Monteiro RC, Preud'Homme JL, Lesavre P: Glomerular and serum immunoglobulin G subclasses in membranous nephropathy and anti-glomerular basement membrane nephritis. Clin Immunol Immunopathol 46: 186-194, 1988
19. Imai H, Hamai K, Komatsuda A, Ohtani H, Miura AB: IgG subclasses in patients with membranoproliferative glomerulonephritis,membranous nephropathy, and lupus nephritis. Kidney Int 51: 270-276, 1997
20. Qu Z, Liu G, Li J, Wu LH, Tan Y, Zheng X, Ao J, Zhao MH: Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transplant 27: 1931-1937, 2012
21. Haas M: IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies. Am J Kidney Dis 23: 358-364, 1994
22. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB: Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 18: 984-992, 2012
23. Hönger G, Hopfer H, Arnold ML, Spriewald BM, Schaub S, Amico P: Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation 92: 41-47, 2011
24. Arnold ML, Ntokou IS, Doxiadis II, Spriewald BM, Boletis JN, Iniotaki AG: Donor-specific HLA antibodies: Evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies. Transpl Int 27: 253-261, 2014
25. Kushihata F, Watanabe J, Mulder A, Claas F, Scornik JC: Human leukocyte antigen antibodies and human complement activation: Role of IgG subclass, specificity, and cytotoxic potential. Transplantation 78: 995-1001, 2004
26. Karuppan SS,Ohlman S,Möller E: The occurrence of cytotoxic and noncomplement-fixing antibodies in the crossmatch serum of patients with early acute rejection episodes. Transplantation 54: 839-844, 1992
27. Griffiths EJ, Nelson RE, Dupont PJ, Warrens AN: Skewing of pretransplant anti-HLA class I antibodies of immunoglobulin G isotype solely toward immunoglobulin G1 subclass is associated with poorer renal allograft survival. Transplantation 77: 1771-1773, 2004
28. Bartel G, Wahrmann M, Exner M, Regele H, Schillinger M, Hörl WH, Böhmig GA: Determinants of the complement-fixing ability of recipient presensitization against HLA antigens. Transplantation 83: 727-733, 2007
29. Schaub S, Hönger G, Amico P: The complexity of the humoral immune response against HLA antigens. Transpl Int 27: 249-250, 2014
30. Monteiro F, Mineiro C, Rodrigues H, de Paula FJ, Kalil J: Pretransplant and posttransplant monitoring of anti-HLA class I IgG1 antibodies by ELISA identifies patients at high risk of graft loss. Transplant Proc 29: 1433-1434, 1997
31. Regan J, Monteiro F, Speiser D, Kalil J, Pouletty P, Buelow R: Pretransplant rejection risk assessment through enzyme-linked immunosorbent assay analysis of anti-HLA class I antibodies. Am J Kidney Dis 28: 92-98, 1996
32. ArnoldML, Zacher T, DechantM, Kalden JR, Doxiadis II, Spriewald BM: Detection and specification of noncomplement binding anti-HLA alloantibodies. Hum Immunol 65: 1288-1296, 2004
33. Gao ZH, McAlister VC, Wright JR Jr, McAlister CC, Peltekian K, MacDonald AS: Immunoglobulin-G subclass antidonor reactivity in transplant recipients. Liver Transpl 10: 1055-1059, 2004
34. Lobashevsky A, Rosner K, Goggins W, Higgins N: Subtypes of immunoglobulin (Ig)-Gantibodies against donor class II HLA and cross-match results in three kidney transplant candidates. Transpl Immunol 23: 81-85, 2010
35. Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, Castro MC, David DS, David-Neto E, Bagnasco SM, Cendales LC, Cornell LD, Demetris AJ, Drachenberg CB, Farver CF, Farris AB 3rd, Gibson IW, Kraus E, LiapisH, Loupy A, Nickeleit V, Randhawa P, Rodriguez ER, Rush D, Smith RN, Tan CD, Wallace WD, Mengel M; Banff meeting report writing committee: Banff 2013meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions.Am J Transplant 14: 272-283, 2014
36. Kamisawa T, Zen Y, Pillai S, Stone JH: IgG4-related disease. Lancet : 2014
37. Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM: Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11: 2405-2413, 2011
38. Kocak B, Arpali E,Demiralp E, Yelken B, KaratasC,Gorcin S,Gorgulu N, Uzunalan M, Turkmen A, Kalayoglu M: Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: Case reports. Transplant Proc 45: 1022-1025, 2013
39. Burbach M, Suberbielle C, Brochériou I, Ridel C, Mesnard L, Dahan K, Rondeau E,Hertig A: Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts. Transplantation 98: 1056-1059, 2014
40. Lowe D, Higgins R, Zehnder D, Briggs DC: Significant IgG subclass heterogeneity in HLA-specific antibodies: Implications for pathogenicity, prognosis, and the rejection response. Hum Immunol 74: 666-672, 2013
41. Debiec H, Nauta J, Coulet F, van der Burg M, Guigonis V, Schurmans T, de Heer E, Soubrier F, Janssen F, Ronco P: Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 364: 1252-1259, 2004
42. Ronco P, Debiec H: Molecular dissection of target antigens and nephritogenic antibodies in membranous nephropathy: Towards epitope-driven therapies. J Am Soc Nephrol 17: 1772-1774, 2006
43. Hidalgo LG, Sis B, Sellares J, Campbell PM, Mengel M, Einecke G, Chang J, Halloran PF:NK cell transcripts andNK cells in kidney biopsies from patients with donor-specific antibodies: Evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 10: 1812-1822, 2010
44. Rahimi S, Qian Z, Layton J, Fox-Talbot K, Baldwin WM 3rd, Wasowska BA: Non-complement-and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am J Transplant 4: 326-334, 2004
45. Stegall MD, Chedid MF, Cornell LD: The role of complement in antibodymediated rejection in kidney transplantation. Nat Rev Nephrol 8: 670-678, 2012
46. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461-470, 1999
47. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y, Mihatsch MJ, Nadasdy T, Nickerson P, Olsen TS, Papadimitriou JC, Randhawa PS, Salinas-Madrigal L, Salomon DR, Sund S, Taskinen E, Trpkov K, Yamaguchi Y: The Banff 97 working classification of renal allograft pathology. Kidney Int 55: 713-723, 1999
48. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, KashgarianM, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K: Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 3: 708-714, 2003
49. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M: Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 8: 753-760, 2008
50. Loupy A, Vernerey D, Tinel C, AubertO, Duong van Huyen JP, RabantM, Verine J, Nochy D, Empana JP, Martinez F, Glotz D, Jouven X, Legendre C, Lefaucheur C: Subclinical rejection phenotypes at 1 yearpost-transplant and outcome of kidney allografts. J Am SocNephrol : 2015